Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) reported second quarter 2026 revenue of $344 thousand, down from $591 thousand a year earlier, during its transition from the Platinum platform to the anticipated Proteus protein sequencing system. Gross profit was $172 thousand with a 50% gross margin.
Total operating expenses were $25.8 million versus $30.5 million in Q2 2025, and net loss narrowed to $23.5 million from $28.8 million. Adjusted EBITDA was negative $21.2 million, compared to negative $22.2 million in the prior-year quarter. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $169.9 million.
The company updated the anticipated commercial launch of Proteus to Q2 2027 to allow an additional integrated instrument design cycle and announced a workforce reduction of about 20%, expected to yield roughly $12 million in annualized operating expense savings and extend its cash runway into Q4 2028. Quantum-Si reiterated 2026 guidance, including approximately $1.0 million in revenue and adjusted total operating expenses of $98.0 million or less, and highlighted an estimated $4 billion annual non-human proteomics market opportunity for Proteus.
Quantum-Si (Nasdaq: QSI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. President and CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call and webcast at 4:30 PM EDT to review results and provide a business update.
Investors can access the live webcast via the Investors section of the Quantum-Si website under Events and Presentations or register to receive a dial-in number and personalized PIN. An archived webcast will be available for replay after the event.
Quantum-Si (Nasdaq: QSI) granted 134,141 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, then in 12 equal quarterly installments, subject to continued employment.
Summary not available.
Quantum-Si (Nasdaq: QSI) announced an expanded multi-city roadshow for its Proteus single-molecule protein sequencing platform. The program aims to educate the market, showcase applications, and build a customer funnel ahead of Proteus’ commercial launch.
Stops span major U.S. hubs and key European research centers.
Quantum-Si (Nasdaq: QSI) granted 427,636 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued employment.
Quantum-Si (Nasdaq: QSI) reported Q1 2026 results and Proteus development progress on May 7, 2026. Q1 revenue was $258,000, gross profit $74,000 and net loss $21.7M. Cash and investments totaled $190.4M, expected to fund operations into Q2 2028. Key technical milestone: automated sequencing on integrated Proteus instruments with a developmental kit detecting 17 amino acids; commercial launch targeted end of 2026.
Quantum-Si (Nasdaq: QSI) will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026. Jeff Hawkins, CEO, and Jeff Keyes, CFO, will hold one-on-one meetings; Hawkins will join a fireside chat at 4:00 PM ET.
A live and archived webcast will be available in the company Investors section under Events & Presentations, and registration is offered for the live stream.
Quantum-Si (Nasdaq: QSI) announced successful sequencing on fully integrated Proteus™ instruments using a developmental KinetIQ™ Array sequencing kit that detects 17 amino acids. The company said the run—from reaction setup to data acquisition—was fully automated without user intervention.
Quantum-Si said this advances detection capabilities from 15 to 17 amino acids since December 2025 and reiterated a goal for Proteus commercial launch by end of 2026, with early access for customers planned this summer and ongoing manufacturing scale-up efforts.
Quantum-Si (Nasdaq: QSI) will report first quarter 2026 financial results on May 7, 2026. A conference call and live webcast with CEO Jeff Hawkins and CFO Jeff Keyes will occur the same day at 4:30 PM ET. An archived webcast will be available after the event.
Investors can listen via the Investors section of the company website or register to receive a dial-in number and personalized PIN to participate.